BRPI1013579A2 - derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos - Google Patents

derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos Download PDF

Info

Publication number
BRPI1013579A2
BRPI1013579A2 BRPI1013579-0A BRPI1013579A BRPI1013579A2 BR PI1013579 A2 BRPI1013579 A2 BR PI1013579A2 BR PI1013579 A BRPI1013579 A BR PI1013579A BR PI1013579 A2 BRPI1013579 A2 BR PI1013579A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
methods
derivatives
substituted
receptor
Prior art date
Application number
BRPI1013579-0A
Other languages
English (en)
Inventor
Adnam M.M. Mjalli
Devi Reddy Gohimukkula
Robert Carl Andrews
Stephen Thomas Davis
Thomas Scott Yokum
Jennifer L.R. Freeman
Christopher Behme
Daniel P. Christen
Dharma Rao Polisetti
James Quada
Kalpathy Santhosh
Muralidhar Bondlela
Mustafa Guzel
Revindra ReddY Yarragunta
Original Assignee
Transtech Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma, Inc. filed Critical Transtech Pharma, Inc.
Publication of BRPI1013579A2 publication Critical patent/BRPI1013579A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Secondary Cells (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DERIVADOS DE AZOANTRACENO SUBSTITUÍDOS, COMPOSIÇÕES FARMACÊUTICAS E MÉTODOS DE USO DOS MESMOS A presente invenção é dirigida a derivados de azoantraceno substituídos ou sais farmaceuticamente aceitáveis dos mesmos que modulam o receptor de GLP-1 humano e que podem ser úteis no tratamento de doenças, distúrbios ou condições em que a modulação do receptor de GLP-1 humano é benéfica, tais como diabetes mellitus tipo 2. A invenção também é dirigida a composições farmacêuticas que compreendem tais compostos e ao uso de tais compostos e composições no tratamento de tais doenças, distúrbios ou condições em que a modulação do receptor de GLP-1 humano é benéfica.
BRPI1013579-0A 2009-03-30 2010-03-30 derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos BRPI1013579A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US61/164.523 2009-03-30
US30934810P 2010-03-01 2010-03-01
US61/309.348 2010-03-01
PCT/US2010/029172 WO2010114824A1 (en) 2009-03-30 2010-03-30 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI1013579A2 true BRPI1013579A2 (pt) 2020-11-03

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013579-0A BRPI1013579A2 (pt) 2009-03-30 2010-03-30 derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos

Country Status (17)

Country Link
US (3) US8383644B2 (pt)
EP (1) EP2413693B1 (pt)
JP (1) JP5755217B2 (pt)
KR (1) KR101732978B1 (pt)
CN (1) CN102378574B (pt)
AU (1) AU2010232750B2 (pt)
BR (1) BRPI1013579A2 (pt)
CA (1) CA2757084C (pt)
DK (1) DK2413693T3 (pt)
EA (1) EA023430B1 (pt)
ES (1) ES2553645T3 (pt)
IL (1) IL214822A (pt)
MA (1) MA33219B1 (pt)
MX (1) MX2011010347A (pt)
SG (1) SG174205A1 (pt)
TN (1) TN2011000437A1 (pt)
WO (1) WO2010114824A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010347A (es) 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
AU2012326361B2 (en) 2011-10-17 2017-08-03 Biotheryx, Inc. Substituted biaryl alkyl amides
MX366685B (es) * 2013-01-17 2019-07-19 Vtv Therapeutics Llc Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos.
EP3549582B1 (en) 2014-08-29 2024-10-30 The Board of Regents of The University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
KR20210005843A (ko) * 2018-05-08 2021-01-15 브이티브이 테라퓨틱스 엘엘씨 Glp1r 작용제의 치료적 용도
TWI707683B (zh) * 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
EP4578460A3 (en) * 2019-05-20 2025-08-27 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN120329250A (zh) * 2020-01-20 2025-07-18 新月生物科学 新型细胞代谢调节化合物及其用途
JP2023528565A (ja) 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
WO2021196951A1 (zh) 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
US20230348390A1 (en) 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing methyl(s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenylpropionate and salt thereof
TW202206420A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 用於製備glp-1受體促效劑的中間體和方法
EP4159719A4 (en) * 2020-05-28 2024-07-17 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Preparation method for (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)methyl propionate diacid salt
TW202210486A (zh) 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種製備ｇｌｐ—１受體激動劑的方法
EP4159737A4 (en) * 2020-05-28 2024-10-09 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. METHOD FOR PREPARING A GLP-1 RECEPTOR AGONIST-FREE BASE
WO2021242807A1 (en) 2020-05-28 2021-12-02 Vtv Therapeutics Llc Methods for preparing methyl (s)-2-amino-3-(4-(2,3-dimethylpyridin-4-yl)phenyl)propionate and hydrochloric acid salts thereof
CN119930603A (zh) 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
EP4213847A4 (en) * 2020-09-21 2024-12-04 vTv Therapeutics LLC AMORPHOUS FORM OF AN ISOQUINOLINE DERIVATIVE
WO2022076503A1 (en) * 2020-10-08 2022-04-14 Eli Lilly And Company 6-methoxy-3,4-dihydro-1h-isoquinoline compounds useful in the treatment of diabetes
CN116348464A (zh) 2020-10-12 2023-06-27 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
CN115461334B (zh) 2020-11-27 2024-06-21 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
WO2022199458A1 (zh) 2021-03-22 2022-09-29 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
WO2022262615A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
AU2022300055A1 (en) 2021-06-24 2024-01-18 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1 receptor agonist and composition and use thereof
CN117897387A (zh) * 2021-09-03 2024-04-16 杭州中美华东制药有限公司 Glp-1受体激动剂中间体的制备方法
CN118215478A (zh) 2021-09-08 2024-06-18 盐野义制药株式会社 用于预防和治疗与抗肥胖作用有关的疾病的药物
WO2023051490A1 (zh) 2021-09-28 2023-04-06 杭州中美华东制药有限公司 Glp-1受体激动剂固体组合物
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
DE60205234T2 (de) * 2001-03-27 2006-05-24 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
ES2278064T3 (es) 2001-10-19 2007-08-01 Transtech Pharma Inc. Derivados de beta-carbolina como inhibidores de ptp.
RU2374236C2 (ru) * 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
KR20050114242A (ko) * 2003-03-26 2005-12-05 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체
US7501538B2 (en) * 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2008118935A1 (en) * 2007-03-26 2008-10-02 Neurogen Corporation Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-ones
EP2262364B1 (en) 2008-03-07 2016-03-02 vTv Therapeutics LLC Oxadiazoanthracene compounds for the treatment of diabetes
WO2009126709A1 (en) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands for the glp-1 receptor and methods for discovery thereof
MX2011010347A (es) 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
WO2011156655A2 (en) 2010-06-09 2011-12-15 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
SG174205A1 (en) 2011-10-28
IL214822A (en) 2016-08-31
IL214822A0 (en) 2011-11-30
CA2757084A1 (en) 2010-10-07
CA2757084C (en) 2017-08-29
US9175003B2 (en) 2015-11-03
TN2011000437A1 (en) 2013-03-27
US20110160198A1 (en) 2011-06-30
EP2413693A1 (en) 2012-02-08
DK2413693T3 (en) 2015-11-16
EA201171197A8 (ru) 2014-10-30
KR101732978B1 (ko) 2017-05-08
MX2011010347A (es) 2011-11-29
EA023430B1 (ru) 2016-06-30
JP2012522060A (ja) 2012-09-20
JP5755217B2 (ja) 2015-07-29
AU2010232750A1 (en) 2011-09-08
US20150148539A1 (en) 2015-05-28
AU2010232750B2 (en) 2015-10-29
ES2553645T3 (es) 2015-12-10
EA201171197A1 (ru) 2012-04-30
EP2413693A4 (en) 2012-08-22
CN102378574A (zh) 2012-03-14
EP2413693B1 (en) 2015-09-09
HK1164050A1 (en) 2012-09-21
US8383644B2 (en) 2013-02-26
US20130096150A1 (en) 2013-04-18
KR20120006506A (ko) 2012-01-18
CN102378574B (zh) 2013-11-20
MA33219B1 (fr) 2012-04-02
WO2010114824A1 (en) 2010-10-07
US8987295B2 (en) 2015-03-24
WO2010114824A8 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
BRPI1013579A2 (pt) derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos
BR112012018386A8 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
CL2009000498A1 (es) Compuestos derivados de benzo [f][1,7]naftiridin sustituidos, moduladores de receptor toll; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedad infecciosa, inflamatoria, dermatologica, respiratoria o inmune.
BR112015015468B8 (pt) Composto, e, composição farmacêutica
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
TN2011000209A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
ATE530524T1 (de) Substituierte sulfonamid-derivate
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
BR112013004721A2 (pt) "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3"
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
AR059864A1 (es) Compuesto de benzamida composicion farmaceutica que lo comprende su uso para preparar un medicamento y procedimientos para su preparacion
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
EA201070916A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты
EA200970022A1 (ru) Комбинированные препараты, содержащие бифепрунокс и l-допу
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators
WO2009134668A3 (en) 4-oxo-1,4-dihydroquinoline m1 receptor positive allosteric modulators

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 61/164,532 E US 61/309,348 POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2589, DE 18/08/2020.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 35/00 , A61K 31/12

Ipc: C07D 319/20 (2006.01), C07D 491/056 (2006.01), C07

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B25C Requirement related to requested transfer of rights

Owner name: TRANSTECH PHARMA, INC. (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 860140129525 DE 31/07/2014, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25B Requested transfer of rights rejected

Owner name: TRANSTECH PHARMA, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 860140129525 DE 31/07/2014, EM VIRTUDE DA MANUTENCAO DO ARQUIVAMENTO (8.11) PUBLICADO NA RPI2618 DE 09/03/2021.

B25E Requested change of name of applicant rejected

Owner name: TRANSTECH PHARMA, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 860150284556 DE 02/12/2015, EM VIRTUDE DA MANUTENCAO DO ARQUIVAMENTO (8.11) PUBLICADO NA RPI2618 DE 09/03/2021.

B25B Requested transfer of rights rejected

Owner name: TRANSTECH PHARMA, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 87016024391 DE 31/05/2016, EM VIRTUDE DA MANUTENCAO DO ARQUIVAMENTO (8.11) PUBLICADO NA RPI2618 DE 09/03/2021.

B350 Update of information on the portal [chapter 15.35 patent gazette]